4-Chloro-6-methoxyquinolin-7-ol is a quinoline derivative characterized by a chloro substituent at the 4-position, a methoxy group at the 6-position, and a hydroxyl group at the 7-position. This specific substitution pattern makes it a valuable and versatile heterocyclic building block in medicinal chemistry. Its primary and most significant application is as a key synthetic intermediate in the production of various pharmaceutical agents. Most notably, it serves as a crucial precursor in the synthesis of the potent tyrosine kinase inhibitor **Bosutinib** (SKI-606), which is an approved drug for the treatment of chronic myelogenous leukemia (CML). The compound's structure provides the core quinoline scaffold upon which further functionalization is performed to construct the final active pharmaceutical ingredient (API). Beyond its role in Bosutinib synthesis, this intermediate is also explored in the research and development of other kinase inhibitors and biologically active molecules targeting cancer pathways. Its utility underscores the importance of functionalized quinoline derivatives in modern drug discovery, particularly in oncology.